Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment
- 1 March 2007
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 49 (3), 506-510
- https://doi.org/10.1161/01.hyp.0000256530.39695.a3
Abstract
Standard treatment in chronic kidney disease (CKD) patients includes an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. CKD is often characterized by sympathetic hyperactivity. This study investigates the prevalence of sympathetic hyperactivity (quantified by assessment of muscle sympathetic nerve activity [MSNA]) in a sizable group of patients with CKD and assessed whether chronic angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker normalizes increased MSNA. In 74 CKD patients (creatinine clearance 54±31 mL/min), MSNA, blood pressure, and plasma renin activity were measured in the absence of antihypertensive drugs except for diuretics. In a subgroup of 31 patients, another set of measurements was obtained after ≥6 weeks of enalapril (10 mg PO), losartan (100 mg PO), or eprosartan (600 mg PO). Patients as compared with control subjects (n=82) had higher mean arterial pressure (113±13 versus 89±7 mm Hg), MSNA (31±13 versus 19±7 bursts per minute), and log plasma renin activity (2.67±036 versus 2.40±0.32 fmol/L per second; all P P P <0.01). Multiple regression analysis identified age and plasma renin activity as predictive for MSNA. In conclusion, sympathetic hyperactivity occurs in a substantial proportion of hypertensive CKD patients. Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment reduces but does not normalize MSNA.Keywords
This publication has 18 references indexed in Scilit:
- Renin inhibition with aliskiren: where are we now, and where are we going?Journal Of Hypertension, 2006
- Moxonidine Normalizes Sympathetic Hyperactivity in Patients with Eprosartan-Treated Chronic Renal FailureJournal of the American Society of Nephrology, 2004
- Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatmentKidney International, 2004
- Causes and Consequences of Increased Sympathetic Activity in Renal DiseaseHypertension, 2004
- Moxonidine treatment of hypertensive patients with advanced renal failureJournal Of Hypertension, 2003
- Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathyJournal of the American College of Cardiology, 2003
- Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal FailureNew England Journal of Medicine, 1999
- Direct assessment of extracellular water volume by the bromide‐dilution method in growth hormone‐deficient adults*European Journal of Clinical Investigation, 1995
- Elevated plasma catecholamines in hypertensives with primary glomerular diseases.Hypertension, 1983
- Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal diseaseKidney International, 1982